Opendata, web and dolomites

QuickMIC

QuickMIC™ - an ultra-rapid diagnostic system for Antibiotic Susceptibility Testing (AST)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 QuickMIC project word cloud

Explore the words cloud of the QuickMIC project. It provides you a very rough idea of what is the project "QuickMIC" about.

more    standard    death    additionally    rapid    approx    patients    commercializing    diagnosis    samples    antibiotics    tool    hours    sepsis    microfluidics    doctors    guide    misuse    continued    patented    reduce    bacterial    48    market    people    continuous    decrease    million    ce    infection    price    improvement    treating    antibiotic    direct    diagnostic    commercialisation    usually    worldwide    resistance    appropriate    treat    contributes    competitiveness    golden    patient    effort    platform    disease    ed    survival    significantly    gradientech    competitors    time    antimicrobial    business    combining    survive    fastest    blood    ivd    spectrum    tested    detection    plan    unsuccessful    successful    fighting    quickmic    ultra    alternative    trade    image    marking    empirical    amr    besides    susceptibility    escalating    globally    rates    empirically    2019    treatment    contribution    innovation    quicker    clinical    ast    unmet   

Project "QuickMIC" data sheet

The following table provides information about the project.

Coordinator
GRADIENTECH AB 

Organization address
address: UPPSALA SCIENCE PARK
city: UPPSALA
postcode: 75183
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://gradientech.se/funding-horizon-2020-sme-instrument/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GRADIENTECH AB SE (UPPSALA) coordinator 50˙000.00

Map

 Project objective

The aim of the project is to bring QuickMIC™, an ultra-rapid diagnostic tool for Antibiotic Susceptibility Testing (AST) to the market and clinical practice. AST is usually carried out to determine which antibiotic will be the most appropriate in treating a bacterial infection in a particular patient. Sepsis is the major cause of death as a result of an infection today. It affects approx. 30 million of people every year worldwide. About 20 % of the patients do not survive the disease. Currently, it can take up to 48 hours for the current golden standard AST method to produce reliable diagnostic results. Therefore, doctors empirically treat sepsis patients with wide-spectrum antibiotics while the blood samples are being tested. The globally escalating antimicrobial resistance (AMR) has resulted in empirical treatment being unsuccessful more and more often. Misuse of antibiotics additionally contributes to increasing resistance. The improvement of survival rates in sepsis and the decrease in AMR will only be possible with access to a quicker AST tool. To address this unmet clinical need, Gradientech is developing an ultra-rapid AST system, QuickMIC™, based on a patented technology platform. By combining i) advanced microfluidics and ii) continuous image detection and analysis, QuickMIC™ can reduce the time of an AST to two hours. Besides being the fastest AST under development, QuickMIC™ is also a low-price alternative compared to its direct competitors. By commercializing QuickMIC™, Gradientech will make an important contribution to fighting AMR in Europe. Moreover, we will significantly improve the diagnosis and treatment of sepsis. A continued development of QuickMIC™ will result in a CE-IVD marking by early 2019. In the Phase 1 project, we will develop a business plan that will guide the future clinical studies and commercialisation activities. If successful, the overall innovation effort will take Gradientech to a new level of competitiveness and growth.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "QUICKMIC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "QUICKMIC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

MealHero (2019)

Automated cooking for tasty and healthy meals in a convenient way

Read More